Clinical Trials Logo

Clinical Trial Summary

This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-up was terminated in 4 years. To observe the accuracy of circulating free methylated EBV DNA in predicting 2-year PFS rate, 2-year OS rate, and CR rate in newly diagnosed ENKTCL patients; and to clarify the prognostic stratification ability of PINK-cpgE compared with PINK-E


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05343377
Study type Interventional
Source The First Affiliated Hospital with Nanjing Medical University
Contact wei xu
Phone 025-68306034
Email xuwei10000@hotmail.com
Status Not yet recruiting
Phase N/A
Start date June 1, 2022
Completion date June 1, 2028

See also
  Status Clinical Trial Phase
Completed NCT03595657 - A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL) Phase 2